TY - JOUR
T1 - Hyperglycemia during childhood cancer therapy
T2 - Incidence, implications, and impact on outcomes
AU - Grimes, Allison
AU - Mohamed, Ashraf
AU - Sopfe, Jenna
AU - Hill, Rachel
AU - Lynch, Jane
N1 - Publisher Copyright:
© 2019 Published by Oxford University Press 2019.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Hyperglycemia is a known complication of therapies used in the treatment of childhood cancer, particularly glucocorticoids and asparaginase. It has been linked to increased infection and reduced survival. With more limited data on hyperglycemia during childhood cancer treatment compared with adult cancer, impact on outcomes is less clear in this population. As additional glycemic-altering cancer agents including immune checkpoint inhibitors and targeted therapies make their way into pediatric cancer treatment, there is a more pressing need to better understand the mechanisms, risk factors, and adverse effects of hyperglycemia on the child with cancer. Thus, we utilized a systematic approach to review the current understanding of the incidence, implications, and outcomes of hyperglycemia during childhood cancer therapy.
AB - Hyperglycemia is a known complication of therapies used in the treatment of childhood cancer, particularly glucocorticoids and asparaginase. It has been linked to increased infection and reduced survival. With more limited data on hyperglycemia during childhood cancer treatment compared with adult cancer, impact on outcomes is less clear in this population. As additional glycemic-altering cancer agents including immune checkpoint inhibitors and targeted therapies make their way into pediatric cancer treatment, there is a more pressing need to better understand the mechanisms, risk factors, and adverse effects of hyperglycemia on the child with cancer. Thus, we utilized a systematic approach to review the current understanding of the incidence, implications, and outcomes of hyperglycemia during childhood cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=85072300547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072300547&partnerID=8YFLogxK
U2 - 10.1093/jncimonographs/lgz022
DO - 10.1093/jncimonographs/lgz022
M3 - Article
C2 - 31532529
AN - SCOPUS:85072300547
SN - 1052-6773
VL - 2019
SP - 132
EP - 138
JO - Journal of the National Cancer Institute - Monographs
JF - Journal of the National Cancer Institute - Monographs
IS - 54
ER -